RS58133B1 - Čvrsta kombinacija za oralno davanje koja sadrži ibandronsku kiselinu ili njenu farmaceutski prihvatljivu so i vitamin d - Google Patents

Čvrsta kombinacija za oralno davanje koja sadrži ibandronsku kiselinu ili njenu farmaceutski prihvatljivu so i vitamin d

Info

Publication number
RS58133B1
RS58133B1 RS20181592A RSP20181592A RS58133B1 RS 58133 B1 RS58133 B1 RS 58133B1 RS 20181592 A RS20181592 A RS 20181592A RS P20181592 A RSP20181592 A RS P20181592A RS 58133 B1 RS58133 B1 RS 58133B1
Authority
RS
Serbia
Prior art keywords
vitamin
pharmaceutically acceptable
acceptable salt
oral administration
solid composition
Prior art date
Application number
RS20181592A
Other languages
English (en)
Inventor
Serra João Pedro Silva
Isabel Maria Soares
Original Assignee
Tecnimede Sociedade Tecnico Medicinal S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50943510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS58133(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tecnimede Sociedade Tecnico Medicinal S filed Critical Tecnimede Sociedade Tecnico Medicinal S
Publication of RS58133B1 publication Critical patent/RS58133B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5939,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893Tablet coating processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20181592A 2013-05-31 2014-05-30 Čvrsta kombinacija za oralno davanje koja sadrži ibandronsku kiselinu ili njenu farmaceutski prihvatljivu so i vitamin d RS58133B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PT106978A PT106978A (pt) 2013-05-31 2013-05-31 Composição sólida oral contendo ácido ibandrónico e vitamina d
PCT/PT2014/000036 WO2014193255A1 (en) 2013-05-31 2014-05-30 Solid composition for oral administration containing ibandronic acid or a pharmaceutically acceptable salt thereof and vitamin d
EP14730606.2A EP3003383B1 (en) 2013-05-31 2014-05-30 Solid composition for oral administration containing ibandronic acid or a pharmaceutically acceptable salt thereof and vitamin d

Publications (1)

Publication Number Publication Date
RS58133B1 true RS58133B1 (sr) 2019-02-28

Family

ID=50943510

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20181592A RS58133B1 (sr) 2013-05-31 2014-05-30 Čvrsta kombinacija za oralno davanje koja sadrži ibandronsku kiselinu ili njenu farmaceutski prihvatljivu so i vitamin d

Country Status (16)

Country Link
US (1) US20160106766A1 (sr)
EP (1) EP3003383B1 (sr)
BR (1) BR112015029897A2 (sr)
CL (1) CL2015003468A1 (sr)
DK (1) DK3003383T3 (sr)
ES (1) ES2705074T3 (sr)
HU (1) HUE040666T2 (sr)
LT (1) LT3003383T (sr)
MA (1) MA38688B1 (sr)
MX (1) MX364680B (sr)
PL (1) PL3003383T3 (sr)
PT (2) PT106978A (sr)
RS (1) RS58133B1 (sr)
SI (1) SI3003383T1 (sr)
TR (1) TR201821157T4 (sr)
WO (1) WO2014193255A1 (sr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3095447T1 (sl) 2006-02-03 2022-02-28 Opko Renal, Llc Zdravljenje pomanjkanja vitamina D s 25-hidroksivitaminom D2 in 25-hidroksivitaminom D3
DK2037936T3 (da) 2006-06-21 2014-09-22 Opko Renal Llc Fremgangsmåde til behandling og forebyggelse af sekundær hyperparathyroidisme
ES2403107T3 (es) 2007-04-25 2013-05-14 Cytochroma Inc. Método de tratamiento de insuficiencia y deficiencia de vitamina D
KR20190028822A (ko) 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 d 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
DK2552484T3 (da) 2010-03-29 2020-04-14 Opko Ireland Global Holdings Ltd Fremgangsmåder og sammensætninger til reducering af parathyroidniveauer
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 d 방출 제형
EA201790332A1 (ru) 2014-08-07 2017-06-30 Опко Айэлэнд Глобал Холдингз Лтд. Дополнительная терапия 25-гидроксивитамином d
JP7032322B2 (ja) 2016-03-28 2022-03-08 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンd治療法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100317935B1 (ko) 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
WO2003086415A1 (en) 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
JP2010513328A (ja) * 2006-12-20 2010-04-30 ミラン ファーマシューティカルズ ユーエルシー ビタミンdおよびビスホスホン酸を含有する組成物
EP1972341A1 (en) 2007-03-23 2008-09-24 Novartis AG Pharmaceutical compositions comprising a bisphosphonate and vitamin D
US20100158998A1 (en) * 2008-12-23 2010-06-24 Michael Fox Formulations comprising vitamin d or derivatives thereof
EP2416756A2 (en) * 2009-04-10 2012-02-15 Mahmut Bilgic Stable pharmaceutical compositions with high bioavailibility
IT1396937B1 (it) * 2009-11-26 2012-12-20 Bruzzese Formulazioni di bisfosfonati e vitamina d idonee alla somministrazione intermittente per via intramuscolare e sottocutanea
KR101230178B1 (ko) * 2010-06-10 2013-02-06 주식회사 네비팜 골다공증 예방 또는 치료용 조성물 및 이의 제조방법
WO2012117236A1 (en) * 2011-03-02 2012-09-07 D3 Pharma Limited Vitamin d composition

Also Published As

Publication number Publication date
LT3003383T (lt) 2019-03-12
PL3003383T3 (pl) 2019-04-30
SI3003383T1 (sl) 2019-03-29
TR201821157T4 (tr) 2019-02-21
WO2014193255A1 (en) 2014-12-04
EP3003383B1 (en) 2018-10-03
MA38688B1 (fr) 2018-08-31
MX2015016497A (es) 2016-09-08
DK3003383T3 (en) 2019-01-28
PT106978A (pt) 2014-12-02
US20160106766A1 (en) 2016-04-21
MA38688A1 (fr) 2017-07-31
HUE040666T2 (hu) 2019-08-28
ES2705074T3 (es) 2019-03-21
EP3003383A1 (en) 2016-04-13
CL2015003468A1 (es) 2016-07-22
PT3003383T (pt) 2019-01-16
BR112015029897A2 (pt) 2017-07-25
MX364680B (es) 2019-05-03

Similar Documents

Publication Publication Date Title
HUE040666T2 (hu) Ibandronsavat vagy gyógyászatilag elfogadható sóját és D vitamint tartalmazó, orális beadásra alkalmas szilárd kompozíció
HK1223935A1 (zh) 無定形萊特莫韋及其用於口服施用的固體藥物製劑
HK1218884A1 (zh) 用於在口腔中釋放至少種活性藥物成分的固體藥物劑型
HK1200337A1 (en) Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof
HK1248544A1 (zh) 穩定的口服給藥用藥物組合物
EP3020417A4 (en) Pharmaceutical composition for respiratory administration
HK1245646A1 (zh) 口服給藥用醫藥組合物
IL239958A (en) A chewable oral preparation and process for preparing it
HK1232144A1 (zh) 經口給藥用醫藥組合物
EP2979698A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
EP3082783A4 (en) Stable oral pharmaceutical composition
LT2988782T (lt) Dozavimo formos, skirtos peroraliniam veikliųjų medžiagų vartojimui